Clinical Trial Update: Efficacy, Safety, and Tolerability of Once Daily Indacaterol in Chronic Obstructive Pulmonary Disease (COPD) Using Formoterol Twice Daily as Active Control [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating once-daily indacaterol versus twice-daily formoterol as an active control in COPD, reporting efficacy, safety, and tolerability results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Foradil (formoterol)
• Indacaterol (indacaterol)

Snippet

Sponsor: Novartis | Conditions: Chronic Obstructive Pulmonary Disease | Phase 3 | Status: COMPLETED | Results posted: 2011-08-18